Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 0.7x - 0.8x | 0.8x |
| Selected Fwd Ps Multiple | 0.6x - 0.7x | 0.6x |
| Fair Value | ₩6,595 - ₩7,289 | ₩6,942 |
| Upside | 23.5% - 36.5% | 30.0% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| MYUNGMOON Pharm co.,Ltd | - | KOSE:A017180 |
| Daehan Nupharm Co.,Ltd. | - | KOSDAQ:A054670 |
| Korea Arlico Pharm Co.,Ltd. | - | KOSDAQ:A260660 |
| Kyongbo Pharmaceutical Co., Ltd | - | KOSE:A214390 |
| CTCBIO Inc. | - | KOSDAQ:A060590 |
| DongKoo Bio & Pharma Co., Ltd. | - | KOSDAQ:A006620 |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| A017180 | A054670 | A260660 | A214390 | A060590 | A006620 | |||
| KOSE:A017180 | KOSDAQ:A054670 | KOSDAQ:A260660 | KOSE:A214390 | KOSDAQ:A060590 | KOSDAQ:A006620 | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 4.5% | 8.6% | 10.5% | 4.5% | 1.2% | NM- | ||
| 3Y CAGR | 10.6% | 6.7% | 10.8% | 11.8% | 1.0% | 17.1% | ||
| Latest Twelve Months | 8.2% | 2.4% | 6.8% | 2.4% | 7.0% | 5.3% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -5.9% | 6.2% | 3.0% | 0.5% | -7.2% | 4.4% | ||
| Prior Fiscal Year | -2.7% | 6.1% | 1.6% | 1.4% | -11.3% | 5.5% | ||
| Latest Fiscal Year | -1.6% | 7.7% | -2.8% | 1.9% | -3.6% | 0.8% | ||
| Latest Twelve Months | -2.0% | 6.2% | -1.6% | 1.0% | -3.0% | -1.2% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 24.2x | 5.7x | 23.9x | 10.3x | 38.4x | 8.2x | ||
| Price / LTM Sales | 0.3x | 0.5x | 0.4x | 0.5x | 1.1x | 0.6x | ||
| LTM P/E Ratio | -15.1x | 8.6x | -23.4x | 53.2x | -37.1x | -47.7x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 0.3x | 0.5x | 1.1x | |||||
| Historical LTM P/S Ratio | 0.5x | 0.8x | 1.6x | |||||
| Selected Price / Sales Multiple | 0.7x | 0.8x | 0.8x | |||||
| (x) LTM Sales | 243,743 | 243,743 | 243,743 | |||||
| (=) Equity Value | 176,624 | 185,920 | 195,216 | |||||
| (/) Shares Outstanding | 27.0 | 27.0 | 27.0 | |||||
| Implied Value Range | 6,531.45 | 6,875.21 | 7,218.97 | |||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 6,531.45 | 6,875.21 | 7,218.97 | 5,340.00 | ||||
| Upside / (Downside) | 22.3% | 28.7% | 35.2% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | A017180 | A054670 | A260660 | A214390 | A060590 | A006620 | |
| Value of Common Equity | 56,728 | 110,037 | 72,037 | 122,164 | 159,472 | 144,405 | |
| (/) Shares Outstanding | 33.4 | 14.0 | 15.3 | 23.9 | 23.9 | 27.0 | |
| Implied Stock Price | 1,697.00 | 7,840.00 | 4,700.00 | 5,110.00 | 6,670.00 | 5,340.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 1,697.00 | 7,840.00 | 4,700.00 | 5,110.00 | 6,670.00 | 5,340.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |